Jennifer M. Kwan, MD/PhD
Assistant Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Overview
I conducted molecular biology research at UC Berkeley to elucidate genetic regulatory elements in innate immune response and gluconeogenesis/lipogenesis in HIV patients on omega 3 supplements --> MSTP (MD/PhD) training with PhD in biochemistry and molecular genetics using animal models to elucidate role of insulin pathway in adipogenesis and tumorigenesis --> T32 training with IRB approved human translational studies coupled with epidemiological training/studies to try to understand why obesity increases risk of adverse renal transplant/cardio renal outcomes. I harvested human adipose tissue from lean and obese individuals, isolated exosomes/miRNA and lymphocytes via flow cytometry and performed RNA seq transcriptomic analyses to identify differentially expressed and functional pathways. Currently interested/working on translational and big data research in cardio-oncology, to better understand those at risk for adverse cardiovascular effects with goal of improving cardiovascular outcomes of cancer patients, particularly patients on new tyrosine kinase inhibitors and immunotherapy such as checkpoint inhibitors.
Medical Research Interests
Academic Achievements & Community Involvement
Teaching & Mentoring
Clinical Care
Overview
Jennifer M. Kwan, MD, PhD, is a cardio-oncologist, a specialty that focuses on cardiovascular side effects caused by cancer treatment. She also has expertise in interpreting cardiac MRIs and CT scans, which helps her gain insights on the effects of cancer and cancer therapy on the heart.
Dr. Kwan grew up interested in medicine and science and engaged in public health and genetics research during her undergraduate years. “I realized I had a passion for medicine and research. And when volunteering in a clinic, I saw we had a limited arsenal to deal with things like genetic cardiomyopathies and getting them back to a good quality of life,” she says. “That is what spurred me to become a physician-scientist and pursue my MD and PhD.”
As someone who loves hiking and being physically active, Dr. Kwan says she was naturally drawn to the idea of how to slow down aging and improve one’s health span. “A healthy cardiovascular system is crucial to living well and keeping our mental faculties well into our old age, which brought me to cardiology as I wanted to keep the heart healthy,” she says. “In my PhD years, I worked in a cancer lab and explored how cancer formed and how cells differentiate into different tissues. The cancer research field, particularly when it comes to precision medicine, moves so quickly compared to cardiology, and I hope to change that.”
During her internal medicine residency, Dr. Kwan took care of two patients who were in their 30s and mothers to young children. Both women developed heart failure due to cancer treatment. “This inspired me to think of who is at risk of cardiac toxicities and what pathways we can target,” Dr. Kwan says, referring to damage to the heart caused by chemotherapy or immunotherapy. “If we can figure that out, we can try to prevent it.”
To further explore this question, Dr. Kwan did a visiting scholar rotation at the University of California-San Francisco to investigate oncologic therapy cardiotoxicities. In working with a multimillion patient dataset, this experience helped her realize the power of big data. She has been incorporating use of large datasets to mine them for insights between genomics and disease states, including in her current research in clonal hematopoiesis of indeterminate potential (CHIP) and other mutations that occur in our cells as we age, called somatic variants.
With age, one’s blood-forming stem cells acquire genetic mutations. This is often harmless, but sometimes, it can lead to CHIP, which can increase the risk of heart disease, heart failure, stroke and blood borne cancer. However, there are no current guidelines or therapies for this condition. Dr. Kwan is investigating CHIP’s prevalence and effects among cancer and heart failure patients and potential therapeutic targets.
“I encourage all of my patients to consider being involved in our research, which is crucial to better understanding their condition and can hopefully improve outcomes for people who come after them,” she says,
Board Certifications
Cardiovascular Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
News
News
- April 12, 2024
Yale Cancer Center Faculty and Trainees Present at AACR Annual Meeting
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- July 19, 2023
New Frontiers in Cardiovascular Research: Jennifer M. Kwan, MD, PhD and Nathan Chen
- June 21, 2023
Physician-Scientists Are “Endangered Species”